Search PubMed⌕ Search

Biomedical subjects

M Aoshima

Publications and source records attributed to M Aoshima.

At least 109 records · Page 6Linked to original sources
PubMed1979

Simplified method for total correction of interrupted aortic arch with ventricular septal defect in infancy.

Type A interrupted aortic arch with a ventricular septal defect (VSD) in a 3-month-old infant was successfully corrected with the aid of profound hypothermia, limited cardiopulmonary bypass, and total circulatory arrest. The aortic arch was reconstructed by side-to-side anastomosis of the ascending aorta and the main pulmonary artery and then creation of a tube from the anastomotic orifice to the patent ductus arteriosus (PDA) by using a superabundant flap of the anterior wall of the main pulmonary artery. The pulmonary arteriotomy and VSD then were closed. The operative field can be approached easily through a median sternotomy with minimum dissection. Cardiac catheterization and angiocardiography 2 months later demonstrated a satisfactory reconstruction of both the aortic arch and the pulmonary artery.

Angiocardiography↗
PubMed1977

N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.

N4-Acyl-1-beta-D-arabinofuranosylcytosines, which are lipophilic antitumor analogs of 1-beta-D-arabinofuranosylcytosine, were dissolved by the use of a detergent, HCO-60, and the differences in the antitumor activities when the drugs were administered in the forms of solution or suspension were compared. N4-Stearoyl-1-beta-D-arabinofuranosylcytosine (NSC 201290), which was the most active compound when administered as an aqueous suspension, diminished in its activities after it had been dissolved into a clear solution, whereas N4-behenoyl-1-beta-D-arabinofuranosylcytosine (NSC 239336) exhibited activities superior to those of the parent compound 1-beta-D-arabinofuranosylcytosine when administered as a solution. Moreover, the high efficacy of this compound was long lasting in the host animal, regardless of the treatment schedules or the presence of the 1-beta-D-arabinofuranosylcytosine-inactivating enzyme, cytidine deaminase.

Animals↗
PubMed1977

Comparative studies on the antitumor activity and the bone marrow toxicity of 1-(beta-D-glucopyranosyl)-3-(2-chloroethyl)-3-nitrosourea and 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose.

Antitumor activity and bone marrow toxicity of a new nitrosourea analog, 1-(beta-D-glucopyranosyl)-3-(2-chloroethyl)-3-nitrosourea (GANU), were compared with those of 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose (Chlorozotocin) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). GANU was found to be highly active against mouse leukemia L-1210 when administered intraperitoneally or intravenously, being the same degree as Chlorozotocin. Even by oral route, GANU exhibited significant activities, whereas Chlorozotocin failed to show any activities by this route. Studies on the bone marrow toxicity as measured by the depression of white blood cell counts and the marrow cellularity revealed that both GANU and Chlorozotocin were less toxic than BCNU. GANU, however, weemed to be rather more toxic than Chlorotocin.

Administration, Oral↗
PubMed1976

Alteration of biologic behavior of a rat leukemia by different routes of passage.

Two clonal leukemia cell lines exhibiting diploidy or tetraploidy were isolated separately from a mother cell population of rat myelogenous leukemia DBLA-6 (induced by 1-butyl-1-nitrosourea), and their biologic characteristics altered during serial iv or ip passages in Donryu rats were examined. In early generations after the establishment of the clones, leukemia-inducing capacities were clearly demonstrated only in the diploid clone and were characterized as follows: a) release of leukemia cells into the peripheral blood after inoculation, and b) infiltration, and growth of leukemia cells in the bone marrow and spleen. After repeated iv passages, however, leukemia-inducing capacity was greater not only in the diploid but also in the tetraploid clone. By serial ip passages, this capacity was never acquired but was gradually lost even in the diploid clone. Cell electrophoretic mobility, cell size, or susceptibility to chemotherapeutic agents were also modified. There was a strong correlation between the routes of passage and the direction of the changes: The iv route enhanced or the ip route suppressed the leukemia-inducing capacity. Chromosome constitutions were also changed.

Alkylating Agents↗
PubMed1976

Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine.

New derivatives of 1-beta-D-arabinofuranosylcytosine were synthesized and their antitumor activities were tested against mouse leukemia L1210. Among the 50 compounds investigated, a series of N4-acyl derivatives with long-chain saturated fatty acids were found to be highly active. The most active derivatives were N4-stearoly-1-beta-D-arabinofuranosylcytosine, which was administered in the form of suspension, and N4-behenoyl-1-beta-D-arabinofuranosylcytosine given in the form of solution. They were superior to the parent compound, 1-beta-D-arabinofuranosylcytosine, in that smaller dosages exhibited strong activities regardless of the treatment schedule, and they were also resistant to cytidine deaminase.

Acylation↗